Journal Cover Nature Medicine
  [SJR: 13.959]   [H-I: 439]   [725 followers]  Follow
    
   Full-text available via subscription Subscription journal
   ISSN (Print) 1078-8956 - ISSN (Online) 1546-170X
   Published by NPG Homepage  [135 journals]
  • Transitory presence of myeloid-derived suppressor cells in neonates is
           critical for control of inflammation
    • Transitory presence of myeloid-derived suppressor cells in neonates is critical for control of inflammation

      Transitory presence of myeloid-derived suppressor cells in neonates is critical for control of inflammation, Published online: 15 January 2018; doi:10.1038/nm.4467

      Myeloid-derived suppressor cells are induced in newborn mice by breast-milk-derived lactoferrin and confer protection in a model of necrotizing enterocolitis. Their frequency and suppressive activity is decreased in very low-weight infants.Transitory presence of myeloid-derived suppressor cells in neonates is critical for control of inflammation, Published online: 2018-01-15; doi:10.1038/nm.44672018-01-15
      DOI: 10.1038/nm.4467
       
  • Prevention of tuberculosis in rhesus macaques by a cytomegalovirus-based
           vaccine
    • Prevention of tuberculosis in rhesus macaques by a cytomegalovirus-based vaccine

      Prevention of tuberculosis in rhesus macaques by a cytomegalovirus-based vaccine, Published online: 15 January 2018; doi:10.1038/nm.4473

      Complete vaccine-mediated immune control of highly pathogenic Mycobacterium tuberculosis is possible if immune effector responses can intercept the infection at its earliest stages.Prevention of tuberculosis in rhesus macaques by a cytomegalovirus-based vaccine, Published online: 2018-01-15; doi:10.1038/nm.44732018-01-15
      DOI: 10.1038/nm.4473
       
  • Positively selected enhancer elements endow osteosarcoma cells with
           metastatic competence
    • Positively selected enhancer elements endow osteosarcoma cells with metastatic competence

      Positively selected enhancer elements endow osteosarcoma cells with metastatic competence, Published online: 15 January 2018; doi:10.1038/nm.4475

      Peter Scacheri and colleagues report that the activity of enhancer elements in metastatic osteosarcoma is distinct from that in primary tumors and plays a functional role in metastatic progression of osteosarcoma.Positively selected enhancer elements endow osteosarcoma cells with metastatic competence, Published online: 2018-01-15; doi:10.1038/nm.44752018-01-15
      DOI: 10.1038/nm.4475
       
  • Pharmacological blockade of ASCT2-dependent glutamine transport leads to
           antitumor efficacy in preclinical models
    • Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacy in preclinical models

      Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacy in preclinical models, Published online: 15 January 2018; doi:10.1038/nm.4464

      A small molecule selectively targeting the cell-surface glutamine transporter ASCT2 disrupts glutamine signaling and metabolism. This compound displays low toxicity and strong antitumor activity in preclinical in vitro and in vivo models, thus holding promise as a treatment for glutamine-dependent tumors in a clinical setting.Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacy in preclinical models, Published online: 2018-01-15; doi:10.1038/nm.44642018-01-15
      DOI: 10.1038/nm.4464
       
  • Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug
           conjugate and BRAF/MEK inhibitors
    • Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors

      Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors, Published online: 15 January 2018; doi:10.1038/nm.4472

      Expression of AXL earmarks melanoma cells resistant to BRAF and MEK inhibitors that either pre-exist in treatment-naive tumors or emerge in response to therapy. The combination of an AXL-MMAE antibody-drug conjugate with BRAF and MEK inhibitors eliminates heterogeneous melanoma cell populations and prolongs survival in experimental in vivo models at tolerable toxicity. This approach is currently being tested in clinical trials and provides insights into the therapeutic targeting of intra-tumor heterogeneity.Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors, Published online: 2018-01-15; doi:10.1038/nm.44722018-01-15
      DOI: 10.1038/nm.4472
       
  • A small-molecule inhibitor of the ubiquitin activating enzyme for cancer
           treatment
    • A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment

      A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment, Published online: 15 January 2018; doi:10.1038/nm.4474

      Hyer et al. generate a potent and specific small-molecule inhibitor of the E1 ubiquitin-activating enzyme UBE1 that has antitumor activity in mice against a wide variety of tumor types.A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment, Published online: 2018-01-15; doi:10.1038/nm.44742018-01-15
      DOI: 10.1038/nm.4474
       
  • Genomics in childhood acute myeloid leukemia comes of age
    • Genomics in childhood acute myeloid leukemia comes of age

      Genomics in childhood acute myeloid leukemia comes of age, Published online: 09 January 2018; doi:10.1038/nm.4469

      A Children's Oncology Group study of nearly 1,000 pediatric acute myeloid leukemia (AML) cases reveals marked differences between the genomic landscapes of pediatric and adult AML and offers directions for future work.Genomics in childhood acute myeloid leukemia comes of age, Published online: 2018-01-09; doi:10.1038/nm.44692018-01-09
      DOI: 10.1038/nm.4469
       
  • Correction
    • Correction

      Correction, Published online: 09 January 2018; doi:10.1038/nm0118-5

      CorrectionCorrection, Published online: 2018-01-09; doi:10.1038/nm0118-52018-01-09
      DOI: 10.1038/nm0118-5
       
 
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
 
Home (Search)
Subjects A-Z
Publishers A-Z
Customise
APIs
Your IP address: 54.90.237.148
 
About JournalTOCs
API
Help
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-2016